Sign in to view content

Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results

Peter J. Kertes, MD, FRCS(C)

Video
Published 2020

Related

Long Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Recurrent or Persistent Neovascular Age-Releated Macular Degeneration
ILKAY KILIC MUFTUOGLU, MD
Annual Meeting Talks
2016
Phase 3 Randomized, Double-Masked Studies of Brolucizumab Versus Aflibercept in nAMD: Expanded Primary and Secondary Outcomes From HAWK/HARRIER
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2018
Gene Expression Modifications in Anti-VEGF Treated Retinal Müller Cells
Baruch D. Kuppermann, MD, PhD
Annual Meeting Talks
2016

Category: AMD-Neovascular

See more